Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives

Contraception

Volumn 78, Issue 5, 2008, Pages 399-404

  Stolk, Pieter ^a   Schneeweiss, Sebastian ^b   Leufkens, Hubert G M ^a   Heerdink, Eibert R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug reimbursement; Health policy; Oral contraceptives; Pharmacoepidemiology; Policy evaluation

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ESTROGEN; ESTROGEN; GESTODENE; GESTODENE PLUS ESTROGEN; LEVONORGESTREL; LEVONORGESTREL PLUS ESTROGEN; LYNESTRENOL; LYNESTRENOL PLUS ESTROGEN; UNCLASSIFIED DRUG;

ARTICLE; DRUG SUBSTITUTION; GROUPS BY AGE; HEALTH CARE POLICY; NETHERLANDS; ORAL CONTRACEPTION; PHARMACY; REIMBURSEMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; COHORT STUDIES; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL; FEMALE; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NETHERLANDS; PATIENT DROPOUTS; PHARMACOEPIDEMIOLOGY;

EID: 53249109349     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.06.009     Document Type: Article

References (13)

1. Ess S., Schneeweiss S., and Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21 (2003) 89-103
2. Aaserud M., Dahlgren A.T., Kösters J.P., Oxman A.D., Ramsay C., and Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2 (2006) CD005979
3. Djerassi C. The pill: emblem of liberation. BMJ 334 suppl 1 (2007) s15
4. Stolk E.A., and Poley M.J. Criteria for determining a basic health services package - recent developments in the Netherlands. Eur J Health Econom 50 (2005) 2-7
5. De Wolf P., Brouwer W.B.F., and Rutten F.F.H. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?. Int J Health Plann Man 20 (2005) 351-374
6. Facts and figures 2006. The Hague: Stichting Farmaceutische Kengetallen (Foundation for Pharmaceutical Statistics) (2006). http://www.sfk.nl/algemeen/2006fandf [Accessed 16 June 2008]
7. WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. [updated June 2007]. http://www.whocc.no/atcddd/ [Accessed 16 June 2008]
8. Dormuth C., and Schneeweiss S. Rapid monitoring of drug discontinuation rates in response to restrictions in drug reimbursement. Pharmacoepidemiol Drug Saf 13 (2004) S310
9. Foundation for Pharmaceutical Statistics (SFK). The pill. Pharm Weekbl 1307 (2005) [Dutch]
10. Kemmeren J.M., Algra A., and Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 323 (2001) 131-134
11. Oddens B.J., Arnolds H.T., Van Maris M.G.M., and Van Lunsen H.W. The dynamics of oral contraceptive use in the Netherlands 1990-1993. Adv Contracept 10 (1994) 167-174
12. Trifiro G., Alacqua M., Corrao S., et al. Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision. Eur J Clin Pharmacol (2008) [electronic publication ahead of print]
13. Bouvy M.L., and Egberts T.C.G. Consequences of a change in reimbursement status on prescription patterns. Eur J Clin Pharmacol 56 (2000) 511-512